ASC30
A Study to Evaluate the Efficacy, Safety, and Tolerability in Participants With Obesity or Overweight With Weight-Related Comorbidities
Ascletis Pharma (China) Co · Phase 2 · Completed · Enrollment 125
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Cohort 1 | n/r | n/r | n/r | n/r |
| Cohort 2 | n/r | n/r | n/r | n/r |
| Cohort 3 | n/r | n/r | n/r | n/r |
| Cohort 4 | n/r | n/r | n/r | n/r |
| Cohort 5 | n/r | n/r | n/r | n/r |
| Cohort 6 | n/r | n/r | n/r | n/r |
| Cohort 7 | n/r | n/r | n/r | n/r |
Not shown
- Cohort 1: endpoint not reported
- Cohort 2: endpoint not reported
- Cohort 3: endpoint not reported
- Cohort 4: endpoint not reported
- Cohort 5: endpoint not reported
- Cohort 6: endpoint not reported
- Cohort 7: endpoint not reported